COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00041067
Recruitment Status : Completed
First Posted : January 27, 2003
Results First Posted : June 6, 2013
Last Update Posted : June 6, 2013
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Southwest Oncology Group

Brief Summary:

RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Colony-stimulating factors, such as filgrastim, may help a person's immune system recover from the side effects of chemotherapy.

PURPOSE: Phase II trial to study the effectiveness of combining trastuzumab with docetaxel, vinorelbine, and filgrastim in treating women who have stage IV breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Biological: filgrastim Biological: trastuzumab Drug: docetaxel Drug: vinorelbine Phase 2

Detailed Description:


  • Determine the 1-year survival of women with HER2-positive stage IV breast cancer treated with trastuzumab (Herceptin), docetaxel, and vinorelbine with filgrastim (G-CSF) support.
  • Determine the response rate (complete and partial, confirmed and unconfirmed) in the subset of patients with measurable disease treated with this regimen.
  • Determine the progression-free survival of patients treated with this regimen.
  • Determine the qualitative and quantitative toxic effects of this regimen in these patients.
  • Obtain tissue blocks for the determination of predictors of response (e.g., beta-tubulin mutations) to microtubule interacting agents in this patient population and for other future studies.

OUTLINE: This is a pilot, multicenter study.

Patients receive docetaxel IV over 1 hour on day 1, filgrastim (G-CSF) subcutaneously on days 2-21, vinorelbine IV over 6-10 minutes on days 8 and 15, and trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. If docetaxel and vinorelbine are discontinued due to unacceptable toxicity, patients may continue to receive trastuzumab. If trastuzumab is discontinued due to unacceptable toxicity, patients may continue to receive chemotherapy with G-CSF support.

Patients are followed every 6 months for 3 years.

PROJECTED ACCRUAL: A total of 90 patients will be accrued for this study within 18-22.5 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 76 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Docetaxel (NSC-628503) And Vinorelbine (NSC-608210) Plus Filgrastim (NSC-614629) With Weekly Trastuzumab (NSC-688097) For HER-2 Positive, Stage IV Breast Cancer
Study Start Date : September 2002
Actual Primary Completion Date : January 2008
Actual Study Completion Date : January 2012

Arm Intervention/treatment
Experimental: Trastuzumab, docetaxel, vinorelbine and filgrastim
Trastuzumab, docetaxel, vinorelbine and filgrastim
Biological: filgrastim
Biological: trastuzumab
Drug: docetaxel
Drug: vinorelbine

Primary Outcome Measures :
  1. Survival at 1 Year [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Response Rate (Complete and Partial, Confirmed and Unconfirmed) [ Time Frame: response assessed after every 3 cycles (9 weeks) during treatment for up to 3 years if no progession ]
    Response was measured by the RECIST criteria. A patient was considered a responder if there was confirmed or unconfirmed partial or complete response. All others were considered non-responders even if the patient was technically not assessable due to different measurement techniques at the two time points.

  2. Progression-free Survival [ Time Frame: 2 years ]
  3. Toxicity [ Time Frame: toxicities assessed every 3 weeks during treatment, for up to 3 years if no progession ]
    Number of patients for whom highest grade of toxicity observed during treatment. Only adverse events that are possibly, probably or definitely related to study drug are reported.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Histologically confirmed stage IV breast cancer

    • Metastasis to the ipsilateral supraclavicular lymph nodes allowed
  • HER2-positive by fluorescence in situ hybridization (FISH) or immunohistochemistry 3+ staining confirmed in the adjuvant or metastatic setting
  • No effusions or ascites as only sites of disease
  • No primary or metastatic brain or central nervous system tumor
  • Hormone receptor status:

    • Not specified



  • 18 and over


  • Female

Menopausal status:

  • Not specified

Performance status:

  • Zubrod 0-2

Life expectancy:

  • Not specified


  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3


  • Bilirubin normal
  • aspartate aminotransferase or Alanine aminotranferease no greater than 1.5 times upper limit of normal (ULN)
  • Alkaline phosphatase no greater than 2.5 times ULN


  • Not specified


  • left ventricular ejection fraction normal by multigated radionuclide angiography or echocardiogram (patients who have received prior anthracycline therapy)
  • No clinical evidence or history of cardiomyopathy


  • No pre-existing grade 2 or greater motor or sensory peripheral neuropathy except abnormalities due to cancer
  • No prior severe hypersensitivity reaction to docetaxel or other drugs formulated with Polysorbate 80
  • No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or other adequately treated stage I or II cancer currently in complete remission
  • No known sensitivity to E. coli-derived proteins
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception


Biologic therapy:

  • Not specified


  • At least 6 months since prior chemotherapy
  • Prior anthracycline as adjuvant therapy allowed
  • No prior cumulative dose of doxorubicin more than 360 mg/m^2
  • No prior cumulative dose of epirubicin more than 720 mg/m^2
  • No more than 1 prior adjuvant or neoadjuvant chemotherapy regimen for primary disease
  • No prior docetaxel
  • No prior vinorelbine
  • Prior paclitaxel allowed

Endocrine therapy:

  • Prior hormonal therapy as adjuvant therapy or for metastatic breast cancer allowed
  • No concurrent hormonal therapy


  • At least 3 weeks since prior radiotherapy


  • At least 2 weeks since prior surgery and recovered

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00041067

Show Show 145 study locations
Sponsors and Collaborators
Southwest Oncology Group
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Joseph J. Kash, MD Edward Hospital Cancer Center
Publications of Results:
Layout table for additonal information
Responsible Party: Southwest Oncology Group Identifier: NCT00041067    
Other Study ID Numbers: CDR0000069440
S0215 ( Other Identifier: SWOG )
U10CA032102 ( U.S. NIH Grant/Contract )
First Posted: January 27, 2003    Key Record Dates
Results First Posted: June 6, 2013
Last Update Posted: June 6, 2013
Last Verified: May 2013
Keywords provided by Southwest Oncology Group:
stage IV breast cancer
recurrent breast cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological
Antineoplastic Agents, Phytogenic